Iron, transferrin and ferritin were measured in serum samples from 16 patients with primary hypogammaglobulinaemia. Transferrin saturation was low in 12 patients (75%) and serum ferritin was low in 9 patients (56.25%). Both parameters were low, confirming the state of iron deficiency, in 6 patients (37.5%). These figures are highly significant (P<0.01) when compared with the prevalence of iron deficiency in the general population. Eight patients were maintained on intravenous immunoglobulin infusions and the rest on intramuscular immunoglobulin injections, their mean serum IgG being 4.4 g/l and 2.6 g/l respectively. There was no difference in the prevalence of iron deficiency between the two groups.
Introduction
Antibody-deficiency syndromes, whilst rare, are serious disorders. Unless treated, patients are susceptible to recurrent infections with considerable morbidity and mortality (Hermans et al. 1976 , Thomson & Rees-Jones 1979 . There have been reports relating iron status to susceptibility to bacterial infections (Weinberg 1974 , Lancet 1974 , Pollack 1983 ) but the controversy over whether iron deficiency or excess promotes or hampers infection has not yet been settled (Beutler & Fairbanks 1980 , Stockman 1981 Barclay 1985 , Baltimore et al. 1985 . Iron is required in bacterial multiplication for nucleoprotein synthesis (Baltimore et al. 1982) . Unsaturated transferrin exhibits a bacteriostatic effect; it binds free iron and deprives bacteria of an essential element (Weinburg 1974 , Barclay 1985 . Information is lacking, however, on the iron status in patients vulnerable to frequent bacterial infections, particularly patients with primary antibody-deficiency syndromes.
We studied two groups of patients with hypogammaglobulinaemia who had been maintained in a clinically reasonable state over a period of at least eighteen months on either intramuscular or intravenous immunoglobulin therapy. Serum immunoglobulins were correlated with parameters of iron metabolism and the results of the two groups compared.
Methods
Patients suffering from primary hypoor agammaglobulinaemia were included in the study regardless of whether the disorder was of sex-linked or common-variable type. Patients were treated with one of two immunoglobulin products prepared by the Protein Fractionation Centre of the Scottish National Blood Transfusion Service. The intravenous immunoglobulin is mildly treated with pepsin at pH 4, stabilized with maltose and freeze-dried. The product after reconstitution with water is a solution of 5% (5 g/l00 ml) of monomeric intact immunoglobulin. Patients with primary hypogammaglobulinaemia received 200-400 mg/kg every 2-5 weeks infused at a rate of 1.2 mg/kg/min. The intramuscular immunoglobulin is made of unmodified Conn's fraction II in liquid form as 15% solution, and was injected at a dose of 25-50 mg/kg weekly.
Venous blood samples were drawn immediately before immunoglobulin infusions or injections and collected in plain containers. The following analyses were carried out on serum from CV =common variable immunodeficiency. XL = sex-linked immunodeficiency. i.v. = intravenous, i.m. = intramuscular. Reference range (adult): IgA=0.6-3.5 g/l, IgM =0.5-3 g/l, IgG= 6-15 g/l clotted samples: total protein, albumin, globulin, protein electrophoresis, immunoglobulin A, G, M, serum iron and transferrin. Serum ferritin was measured by radioimmunoassay. The saturation percentage of transferrin with iron was calculated.
Results
The patients' age, sex, diagnosis, serum proteins, immunoglobulin levels and types of immunoglobulin therapy are presented in Table 1 . Patients maintained on intravenous immunoglobulin had higher serum immunoglobulin levels of 4.4 + 1.4 g/l (mean + s.e. mean) than those maintained on the intramuscular preparation (2.6 + 0.9 g/1). Serum protein electrophoresis showed gross reduction in gammaglobulin fraction in all patients. Table 2 shows the results for serum ferritin, serum iron, serum transferrin and transferrin saturation. Out of 16 patients, 12 (75%) had low transferrin saturation while 9 (56.25%) had low serum ferritin. Six patients (37.5%) had both low serum ferritin and low transferrin saturation, thus confirming their state of iron deficiency (Cook 1982 , Peter & Wang 1981 . Three of the 6 patients are receiving intravenous immunoglobulin therapy, whilst the other three are maintained on the intramuscular preparation.
Discussion
The prevalence of iron deficiency among the patients studiedof 75% as determined by transferrin saturation, or of 56.25% as determined by serum ferritin, or of 37.5% as determined by both measurementsis highly significant (P< 0.01) when compared with the prevalence of iron deficiency in the general population (Cook et al. 1976 , Jacobs et al. 1972 . It is noteworthy that there was no difference in the incidence of iron deficiency between patients maintained on intramuscular or intravenous immunoglobulin therapy.
The mechanism responsible for iron deficiency in antibody-deficient patients is not known. We postulate five possibilities. The first is the existence of an as yet unknown mechanism which aims to raise the resistance of immunodeficient patients by rendering them irondeficient. Iron deficiency may well compensateto a certain extentfor their increased susceptibility to infection (Pollack 1983 , Barclay 1985 ; however, the existence of such a Reference range: serum ferritin =20-300 ng/ml, serum iron (male) = 9-30 umol/l; (female) = 8-25 pmol/l, serum transferrin = 2-4 g/l, transferrin saturation >20% deliberate mechanism seems unlikely. A second possibility is that the very abnormality which makes them unable to produce antibodies may interfere with iron absorption, possibly through production of a state of excess or deficit of a protein whose function is to inhibit or facilitate (respectively) iron absorption. Thirdly, gammaglobulins may play a physiological role in iron absorption. Hypogammaglobulinaemia, therefore, could lead to iron deficiency. The most likely mechanisms, however, are general or specific iron malabsorption. A general malabsorption state has been observed in 10% of cases of sex-linked agammaglobulinaemia (Hayward 1982) and in an even higher proportion of patients with the common-variable type of hypogammaglobulinaemia (Hermans et al. 1976 , Hayward 1982 . Diarrhoea and malabsorption in these patients has been attributed to overgrowth of the normal enteric bacterial flora (Webster 1976 , Ament & Rubin 1976 , bacterial, protozoal or fungal infections (Hermans et al. 1976 , Webster 1976 . Giardiasis, to which antibody-deficient patients are particularly prone (Hermans et al. 1976 , Thomson & Rees-Jones 1979 , Hughes et al. 1971 , affects the upper small intestine and may only be recovered in the jejunal aspirate (Wright 1983) . The upper small intestine is the site where iron absorption takes place (Jacobs & Worwood 1982) . Patients with common-variable hypogammaglobulinaemia frequently have hypochlorhydria or achlorhydria (Twomey & Jordan 1970 , Dolby et al. 1984 ). The generalized autoimmune process that diminishes immunoglobulin production also leads to loss of the acid-producing parietal cells of the stomach (Kinlen 1985 , MRC 1970 . Iron absorption, particularly in the ferric form, is known to be impaired in patients with hypochlorhydria (Jacobs & Worwood 1982) .
Parenteral immunoglobulin replacement has been shown to protect immunoglobulindeficient patients against infection (Hermans et al. 1976 , Thomson & Rees-Jones 1979 . The conferred protection correlates with the administered dose (MRC 1970) . Before the advent of intravenous immunoglobulin, plasma infusion and then immunoglobulin injected intramuscularly were the mainstay of therapy (Hayward 1982) . Pain limited the injectable dose, whilst volume expansion limited the amount of plasma infused (Magilavy et al. 1978) . Other workers have demonstrated a superior clinical efficacy (i.e. in terms of days of absence from work or sputum volume) and higher serum levels attained by the use of the higher doses of intravenous immunoglobulin compared to the small doses of intramuscular immunoglobulin (Magilavy et al. 1978 , Notle et al. 1979 , So et al. 1984 . The patients studied, however, were switched from one form of treatment to the other over short periods (three or six months); therefore the results obtained may not have been truly representative, especially if the expected seasonal variation in the incidence of infections (mainly respiratory) is taken into consideration.
If the susceptibility to infection is a function of the serum immunoglobulin level, it is important to establish the serum levels achieved by either forms of immunoglobulin therapy used for a prolonged period without alteration to avoid the possibility of carry-over of immunoglobulin from one period to the other. We studied patients who have been maintained on either intravenous or intramuscular immunoglobulin therapy for over eighteen months. The results clearly establish the higher serum level achieved by the intravenous as compared to the intramuscular preparation and route of administration.
It is concluded that if the attendant morbidity of iron deficiency (Jacobs & Worwood 1982 , Pollitt et al. 1984 ) is to be avoided in patients with antibody-deficiency syndromes, screening and treatment of the diagnosed cases of iron deficiency should occur concurrently with the immunoglobulin (preferably intravenous) replacement therapy. Treatment of iron deficiency has not been shown conclusively to enhance the susceptibility to infection (Baltimore et al. 1982 ); on the contrary, treatment may enhance resistance to infection by improving the defective polymorph and lymphocyte functions associated with iron deficiency (Beutler & Fairbanks 1980) .
